AMBULERO
Ambulero, Inc is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease.
AMBULERO
Industry:
Biotechnology Genetics Life Science Therapeutics
Founded:
2019-01-01
Address:
Miami, Florida, United States
Country:
United States
Website Url:
http://www.ambulero.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
5.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Euro Microsoft Exchange Online Google GStatic Google Static Content
Similar Organizations
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Current Employees Featured
Founder
Investors List
Orphinic Scientific
Orphinic Scientific investment in Seed Round - Ambulero
Official Site Inspections
http://www.ambulero.com
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.107
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Ambulero"
Ambulero - Crunchbase Company Profile & Funding
Organization. Ambulero . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Ambulero is a cell and gene therapy spin-out of …See details»
Investors and Development | Ambulero
Ambulero will file an IND for our lead gene therapy product AMB-301 by late 2024. INVESTORS AND DEVELOPMENT. Ambulero is a pioneer in the use of gene and cell therapy approaches …See details»
Board and Advisors | Ambulero
He is leading our non-clinical work to IND for Ambulero’s gene and cell therapy programs. Khemraj Hirani. Chief Regulatory Officer >21 years of investigational drugs/biologics experience from bench to clinic. Principal strategic and …See details»
Ambulero Company Profile 2024: Valuation, Funding & Investors
Ambulero General Information Description. Operator of a biotechnology company intended to develop new ways to treat vascular tissue disease. The company specializes in developing …See details»
Ambulero - LinkedIn
Ambulero is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease. We are a platform company that can deliver the adhesion ...See details»
Ambulero - Funding, Financials, Valuation & Investors - Crunchbase
Ambulero is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease. Search Crunchbase. ... How much funding has this …See details»
Ambulero - Company Profile - Tracxn
Nov 21, 2024 Ambulero - Developer of cell & gene therapies for the treatment of rare vascular disease and critical limb ischemia. Raised a total funding of $5.5M over 2 rounds from 2 …See details»
Ambulero - Contacts, Employees, Board Members, Advisors
Ambulero is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease. ... Chrome Extension. Solutions. Products. Resources. …See details»
Ambulero - Company Profile & Staff Directory - ContactOut
Ambulero is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease. We are a platform company that can deliver the adhesion …See details»
Ambulero - Longevity List
Ambulero is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease. We are a platform company that can deliver the adhesion …See details»
Ambulero Raises Up To $5.5 Million from Orphinic Scientific
Jan 26, 2021 Ambulero is a biotechnology company dedicated to advancing a platform of cell and gene therapies to treat serious vascular diseases. The company is a 2019 spin-out of the …See details»
Ambulero Finishes Second for Prestigious Cade Prize
Oct 11, 2022 Ambulero was nominated by the University of Miami for the award. About Ambulero Ambulero is a privately held biotechnology company advancing a new platform of …See details»
NIH Approves Second Phase of Funding to Support IND
Jun 12, 2023 MIAMI--(BUSINESS WIRE)--Ambulero, Inc. is developing a first-in-class gene and cell therapy platform for treating serious vascular diseases and non-healing wounds where …See details»
Ambulero’s Gene Therapy Candidate AMB-301 Granted US …
Oct 19, 2021 Ambulero Inc Receives Key FDA Recognition For Novel Gene Therapy To Treat Buerger’s Disease (Thromboangiitis Obliterans)MIAMI, Oct. 19, 2021 (GLOBE NEWSWIRE) -- …See details»
Investors and Development | Ambulero
Ambulero will file an IND for our lead gene therapy product AMB-301 by late 2024. INVESTORS AND DEVELOPMENT. Ambulero is a pioneer in the use of gene and cell therapy approaches …See details»
Ambulero Receives Positive Pre-IND Response from FDA for AMB …
Sep 27, 2022 Ambulero is a privately-held biotechnology company advancing a new gene and cell therapy platform to treat serious vascular diseases. The Company is sourcing new …See details»
Scams Details - Better Business Bureau
Dec 2, 2024 This content is based on victim and potential victim accounts. Government agencies and legitimate business names and phone numbers are often used by scam artists to take …See details»
Media Center - Ambulero
Jul 22, 2024 Ambulero announces expansion of its Scientific Advisory Board with the addition of Tim Kelly, Ind ustry Leader in AAV Technology Ambulero is a first-in-class gene & cell therapy …See details»
Pipeline - Ambulero
We estimate that roughly 2 million people in the US have CLI and about 5-10% will have an amputation as part of their care. Ambulero is working with outside research organizations to …See details»